MERIDEN — Vaccine and biopharmaceutical developer Protein Sciences has scored major funding for research into lung cancer treatments.

The company received a $669,156 grant from the U.S. Department of Health and Human Services’ National Cancer Institute, through its Small Business Innovation Research (SBIR) program.

The company will use the money, partnering with the University of California/Los Angeles (UCLA) and Beverly Hills biopharmaceutical company Vault Nano, to produce vaults (barrel-shaped molecular capsules) that deliver chemokine protein treatments directly to cancerous cells, while stimulating the immune system to identify and attack the cancer cells.

The company used similar technology to develop its flu vaccine Flublok. The new cancer drug is in early stage research.